<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036060</url>
  </required_header>
  <id_info>
    <org_study_id>ABIDO-SOGUG</org_study_id>
    <nct_id>NCT02036060</nct_id>
  </id_info>
  <brief_title>Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.</brief_title>
  <acronym>ABIDO</acronym>
  <official_title>Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Randomized Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most frequently diagnosed non-skin cancer, and the second leading
      cause of men cancer death in the United States. Hormonal therapy remains a first-line
      treatment for metastatic prostate cancer. Initial responses to hormonal therapy with chemical
      or surgical castration are quite favorable, however, most patients will progress to a
      castration-resistant phase of the disease. Docetaxel is the primary chemotherapeutic option
      for patients with mCRPC.

      Abiraterone is a novel, selective, irreversible, and potent inhibitor of
      17-[alpha]-hydroxylase/17,20-lyase (CYP17) enzymatic activity that has recently been
      demonstrated to further reduce testosterone levels in the blood to undetectable range (&lt; 1
      ng/dL) and is suggested to reduce de novo intratumor androgen synthesis. Abiraterone
      demonstrated activity in castration resistant prostate cancer patients previously treated
      with docetaxel chemotherapy. Recently, results of a phase III trial comparing abiraterone
      plus prednisone vs placebo plus prednisone in asymptomatic and without visceral metastasis,
      castration-resistant metastatic prostate cancer patients, demonstrated a better radiological
      progression free survival for abiraterone treated patients and a trend towards a better
      survival was clear for abiraterone treated patients.

      No clinical evidence exists about efficacy of chemotherapy and antiandrogen therapy
      combination. All trials have been performed in patients in which LHRH agonist treatment was
      continued although there is not clear evidence about efficacy of hormonal treatment. Some
      retrospective studies suggest that androgen deprivation treatment should be maintained in
      chemotherapy treated patients. Abiraterone has been proved to suppress androgen levels to
      negative values, and to add efficacy to castration hormonal therapy. Combination of
      abiraterone with docetaxel chemotherapy seems promising adding efficacy to only docetaxel
      chemotherapy. A randomized phase II study comparing docetaxel + prednisone + abiraterone to
      docetaxel + prednisone in mCRPC in patients treated previously with abiraterone, seems
      promising to explore addition of efficacy to taxotere after abiraterone hormonal treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year radiologic progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time from randomization to radiologic disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic progression free survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Time from randomization to radiologic progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA progression free survival</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Time from randomization to PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>50% &amp; 90% PSA reduction from randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Response according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Quality of life according to FACT-P questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to skeletal-related event</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Time from randomization to skeletal-related events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to opiate use for cancer pain</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Time from randomization to opiate use for cancer pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Time from randomization to pain progression defined as an increase in median BPI score ≥ 30% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Related adverse events per patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 75 mg/m2 + prednisone 10 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d</intervention_name>
    <description>Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel 75 mg/m2 + prednisone 10 mg/d</intervention_name>
    <description>Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Male aged 18 years and above

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.

          -  Metastatic disease documented by positive bone scan or metastatic lesions other than
             liver or visceral metastasis on CT, MRI.

          -  Prostate cancer progression to previous castration treatment documented by PSA
             according to PCWG2 or radiographic progression according to modified RECIST criteria
             or bone scan progression

          -  Asymptomatic or mildly symptomatic from prostate cancer

          -  Surgically or medically castrated, with testosterone levels of &lt; 50 ng/dL (&lt; 2.0 nM).

          -  Previous anti-androgen therapy and progression after withdrawal.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Hemoglobin &gt;= 10.0 g/dL independent of transfusion

          -  Platelet count &gt;= 100,000/µL

          -  Serum albumin &gt;= 3.5 g/dL

          -  Serum creatinine &lt; 1.5 x ULN or a calculated creatinine clearance &gt;= 60 mL/min

          -  Serum potassium &gt;= 3.5 mmol/L

          -  Liver function: a. Serum bilirubin &lt; 1.5 x ULN (except for patients with documented
             Gilbert's disease) b. AST or ALT &lt; 2.5 x ULN

          -  Life expectancy of at least 6 months

          -  Patients who have partners of childbearing potential must be willing to use a method
             of birth control

        Exclusion Criteria:

          -  Active infection or other medical condition that would make prednisone/prednisolone
             (corticosteroid) use contraindicated

          -  Any chronic medical condition requiring a higher dose of corticosteroid than 10mg
             prednisone/prednisolone daily.

          -  Pathological finding consistent with small cell carcinoma of the prostate

          -  Liver or visceral organ metastasis

          -  Known brain metastasis

          -  Use of opiate analgesics for cancer-related pain, including codeine and
             dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1

          -  Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC

          -  Radiation therapy for treatment of the primary tumor within 6 weeks of Cycle 1, Day

          -  Radiation or radionuclide therapy for treatment of metastatic CRPC

          -  Previously treated with ketoconazole for prostate cancer for greater than 7 days

          -  Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4
             weeks of Cycle 1, Day 1

          -  Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1

          -  Bicalutamide (Casodex), nilutamide (Nilandron) within 6 weeks of Cycle 1 Day 1

          -  Uncontrolled hypertension (systolic BP &gt;= 160 mmHg or diastolic BP &gt;= 95 mmHg).

          -  Active or symptomatic viral hepatitis or chronic liver disease

          -  History of pituitary or adrenal dysfunction

          -  Clinically significant heart disease

          -  Atrial Fibrillation, or other cardiac arrhythmia requiring therapy

          -  Other malignancy, except non-melanoma skin cancer, with a &gt;= 30% probability of
             recurrence within 24 months

          -  Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1

          -  Any condition which, in the opinion of the investigator, would preclude participation
             in this trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Climent, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundación Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A Arranz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel E Castellano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO 12 DE OCTUBRE,Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begoña Mellado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CLINIC I PROVINCIAL DE BARCELONA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Font, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELLÓN, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio Esteban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María I Sáez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL VIRGEN DE LA VICTORIA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Santander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO MIGUEL SERVET, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Maroto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL DE LA SANTA CREU I SANT PAU, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aranzazu González del Alba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARI SON ESPASES, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Alonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL RAMÓN Y CAJAL, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Puente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CLÍNICO SAN CARLOS, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martín Lázaro, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEXO HOSPITALARIO UNIVERSITARIO DE VIGO, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Cassinello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO DE GUADALAJARA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María J Méndez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL REINA SOFÍA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignacio Durán, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL VIRGEN DEL ROCIO, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castellón de la Plana</city>
        <state>Castellón</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic prostate cancer</keyword>
  <keyword>Abiraterone acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

